Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 27 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica - rivastigmine genpar patch is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer?s type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 27 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer - rivastigmine gppl patch is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer?s type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 27 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica - rivastigmine apotex patch is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer?s type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica - rivastigmine aml is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer - rivastigmine genpar is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer - rivastigmine gppl is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer - rivastigmine genpar is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica - rivastigmine apotex is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica - rivastigmine gppl is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer - rivastigmine gxp is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.